Last reviewed · How we verify
RYBREVANT (AMIVANTAMAB-VMJW)
RYBREVANT (generic name: AMIVANTAMAB-VMJW) is a drug developed by JANSSEN BIOTECH. It is currently FDA-approved for Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.
At a glance
| Generic name | AMIVANTAMAB-VMJW |
|---|---|
| Sponsor | JANSSEN BIOTECH |
| Target | Epidermal growth factor receptor, Hepatocyte growth factor receptor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
Common side effects
- Rash
- Nail toxicity
- Infusion-related reaction
- Edema
- Musculoskeletal pain
- Stomatitis
- VTE
- Paresthesia
- Fatigue
- Diarrhea
- Constipation
- COVID-19
Serious adverse events
- Decreased albumin
- Increased ALT
- Decreased sodium
- Decreased hemoglobin
- Increased AST
- Increased GGT
- Decreased neutrophils
- Decreased leukocytes
- Decreased platelets
- Decreased potassium
Key clinical trials
- A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY) (Phase 2)
- A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants With Recurrent Inoperable or Metastatic Cutaneous Squamous Cell (Phase 2)
- A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer (Phase 1)
- A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors (Phase 1)
- A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With (Phase 3)
- A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RYBREVANT CI brief — competitive landscape report
- RYBREVANT updates RSS · CI watch RSS
- JANSSEN BIOTECH portfolio CI
Frequently asked questions about RYBREVANT
What is RYBREVANT?
RYBREVANT (AMIVANTAMAB-VMJW) is a pharmaceutical drug developed by JANSSEN BIOTECH, indicated for Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.
What is RYBREVANT used for?
RYBREVANT is indicated for Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.
Who makes RYBREVANT?
RYBREVANT is developed and marketed by JANSSEN BIOTECH (see full JANSSEN BIOTECH pipeline at /company/johnson-johnson).
What is the generic name of RYBREVANT?
AMIVANTAMAB-VMJW is the generic (nonproprietary) name of RYBREVANT.
What development phase is RYBREVANT in?
RYBREVANT is FDA-approved (marketed).
What are the side effects of RYBREVANT?
Common side effects of RYBREVANT include Rash, Nail toxicity, Infusion-related reaction, Edema, Musculoskeletal pain, Stomatitis. Serious adverse events: Decreased albumin, Increased ALT, Decreased sodium, Decreased hemoglobin.
What does RYBREVANT target?
RYBREVANT targets Epidermal growth factor receptor, Hepatocyte growth factor receptor.
Related
- Target: All drugs targeting Epidermal growth factor receptor, Hepatocyte growth factor receptor
- Manufacturer: JANSSEN BIOTECH — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing